Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis
Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis. To determine the prevalence of neurological and neuropsych...
Gespeichert in:
| Veröffentlicht in: | Journal of the neurological sciences 2022-03, Vol.434, p.120162-120162, Article 120162 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 120162 |
|---|---|
| container_issue | |
| container_start_page | 120162 |
| container_title | Journal of the neurological sciences |
| container_volume | 434 |
| creator | Premraj, Lavienraj Kannapadi, Nivedha V. Briggs, Jack Seal, Stella M. Battaglini, Denise Fanning, Jonathon Suen, Jacky Robba, Chiara Fraser, John Cho, Sung-Min |
| description | Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis.
To determine the prevalence of neurological and neuropsychiatric symptoms reported 12 weeks (3 months) or more after acute COVID-19 onset in adults.
A systematic search of PubMed, EMBASE, Web of Science, Google Scholar and Scopus was conducted for studies published between January 1st, 2020 and August 1st, 2021. The systematic review was guided by Preferred Reporting Items for Systematic Review and Meta-Analyses.
Studies were included if the length of follow-up satisfied the National Institute for Healthcare Excellence (NICE) definition of post-COVID-19 syndrome (symptoms that develop or persist ≥3 months after the onset of COVID-19). Additional criteria included the reporting of neurological or neuropsychiatric symptoms in individuals with COVID-19.
Two authors independently extracted data on patient characteristics, hospital and/or ICU admission, acute-phase COVID-19 symptoms, length of follow-up, and neurological and neuropsychiatric symptoms.
The primary outcome was the prevalence of neurological and neuropsychiatric symptoms reported ≥3 months post onset of COVID-19. We also compared post-COVID-19 syndrome in hospitalised vs. non-hospitalised patients, with vs. without ICU admission during the acute phase of infection, and with mid-term (3 to 6 months) and long-term (>6 months) follow-up.
Of 1458 articles, 18 studies, encompassing a total of 10,530 patients, were analysed. Overall prevalence for neurological post-COVID-19 symptoms were: fatigue (37%, 95% CI: 25%–48%), brain fog (32%, 10%–54%), memory issues (28%, 22%–35%), attention disorder (22%, 7%–36%), myalgia (17%, 9%–25%), anosmia (12%, 8%–16%), dysgeusia (10%, 6%–14%) and headache (15%, 4%–26%). Neuropsychiatric conditions included sleep disturbances (31%, 19%–42%), anxiety (23%, 14%–32%) and depression (17%, 10%–24%). Neuropsychiatric symptoms substantially increased in prevalence between mid- and long-term follow-up. Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety, depression, dysgeusia, fatigue, headache, myalgia, and sleep disturbance at three (or more) months post-infection. Cohorts with >20% of patients admitted to the ICU during acute COVID-19 experienced higher prevalence of f |
| doi_str_mv | 10.1016/j.jns.2022.120162 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8798975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022510X22000211</els_id><sourcerecordid>2626015495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c565t-1612d75d530a884baa48e0680d6c2b354096be69d76c07dac97f9bf19683c2273</originalsourceid><addsrcrecordid>eNp9kU1vFCEYx4nR2LX6AbwYjl5YgVkY0MSkWd-a1PSixhth4JktmxlYgW2y3162Wxu9eCJ5_i888EPoJaNLRpl8s11uY1lyyvmS8Tbgj9CCqV4RoVT3GC1oU4hg9OcZelbKllIqldJP0VknGG8JvUDz1-CxjR5PKW5IhTzjCPucprQJzk530t1gVw7uJtiag8OzjWGEUm0NKRacRrxLpZL19Y_LD4RpXA7R5zTDW3yBZ6iW2GinQwnlOXoy2qnAi_vzHH3_9PHb-gu5uv58ub64Ik5IUQmTjPteeNFRq9RqsHaloO1OvXR86MSKajmA1L6XjvbeOt2PehiZlqpznPfdOXp_6t3thxm8g1izncwuh9nmg0k2mH-VGG7MJt0a1Wule9EKXt8X5PRr355q5lAcTJONkPbFcMklZWKlj1Z2srqcSskwPlzDqDliMlvTMJkjJnPC1DKv_t7vIfGHSzO8Oxmg_dJtgGyKCxAd-JDBVeNT-E_9bxrIpHE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2626015495</pqid></control><display><type>article</type><title>Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Premraj, Lavienraj ; Kannapadi, Nivedha V. ; Briggs, Jack ; Seal, Stella M. ; Battaglini, Denise ; Fanning, Jonathon ; Suen, Jacky ; Robba, Chiara ; Fraser, John ; Cho, Sung-Min</creator><creatorcontrib>Premraj, Lavienraj ; Kannapadi, Nivedha V. ; Briggs, Jack ; Seal, Stella M. ; Battaglini, Denise ; Fanning, Jonathon ; Suen, Jacky ; Robba, Chiara ; Fraser, John ; Cho, Sung-Min</creatorcontrib><description>Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis.
To determine the prevalence of neurological and neuropsychiatric symptoms reported 12 weeks (3 months) or more after acute COVID-19 onset in adults.
A systematic search of PubMed, EMBASE, Web of Science, Google Scholar and Scopus was conducted for studies published between January 1st, 2020 and August 1st, 2021. The systematic review was guided by Preferred Reporting Items for Systematic Review and Meta-Analyses.
Studies were included if the length of follow-up satisfied the National Institute for Healthcare Excellence (NICE) definition of post-COVID-19 syndrome (symptoms that develop or persist ≥3 months after the onset of COVID-19). Additional criteria included the reporting of neurological or neuropsychiatric symptoms in individuals with COVID-19.
Two authors independently extracted data on patient characteristics, hospital and/or ICU admission, acute-phase COVID-19 symptoms, length of follow-up, and neurological and neuropsychiatric symptoms.
The primary outcome was the prevalence of neurological and neuropsychiatric symptoms reported ≥3 months post onset of COVID-19. We also compared post-COVID-19 syndrome in hospitalised vs. non-hospitalised patients, with vs. without ICU admission during the acute phase of infection, and with mid-term (3 to 6 months) and long-term (>6 months) follow-up.
Of 1458 articles, 18 studies, encompassing a total of 10,530 patients, were analysed. Overall prevalence for neurological post-COVID-19 symptoms were: fatigue (37%, 95% CI: 25%–48%), brain fog (32%, 10%–54%), memory issues (28%, 22%–35%), attention disorder (22%, 7%–36%), myalgia (17%, 9%–25%), anosmia (12%, 8%–16%), dysgeusia (10%, 6%–14%) and headache (15%, 4%–26%). Neuropsychiatric conditions included sleep disturbances (31%, 19%–42%), anxiety (23%, 14%–32%) and depression (17%, 10%–24%). Neuropsychiatric symptoms substantially increased in prevalence between mid- and long-term follow-up. Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety, depression, dysgeusia, fatigue, headache, myalgia, and sleep disturbance at three (or more) months post-infection. Cohorts with >20% of patients admitted to the ICU during acute COVID-19 experienced higher prevalence of fatigue, anxiety, depression, and sleep disturbances than cohorts with <20% of ICU admission.
Fatigue, cognitive dysfunction (brain fog, memory issues, attention disorder) and sleep disturbances appear to be key features of post-COVID-19 syndrome. Psychiatric manifestations (sleep disturbances, anxiety, and depression) are common and increase significantly in prevalence over time. Randomised controlled trials are necessary to develop intervention strategy to reduce disease burden.
•Question: How commonly are neurological and neuropsychiatric symptoms reported three months or more after acute COVID-19 onset in adults?•Findings: In a meta-analysis of 18 studies encompassing 10,530 patients (hospitalised and non-hospitalised), overall prevalence for neurological symptoms three months after COVID-19 onset was: fatigue (37%), brain fog (32%), memory issues (28%), attention disorder (22%), myalgia (17%), anosmia (12%), dysgeusia (10%), and headache (15%). The prevalence of neuropsychiatric symptoms was sleep disturbances (31%), anxiety (23%), and depression (17%).•Meaning: Given the high prevalence of neurological and neuropsychiatric post-COVID-19 syndrome, randomised controlled trials are necessary to develop intervention strategy to reduce disease burden.</description><identifier>ISSN: 0022-510X</identifier><identifier>ISSN: 1878-5883</identifier><identifier>EISSN: 1878-5883</identifier><identifier>DOI: 10.1016/j.jns.2022.120162</identifier><identifier>PMID: 35121209</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Anxiety - epidemiology ; Anxiety - etiology ; Anxiety - psychology ; COVID-19 ; COVID-19 - complications ; COVID-19 - epidemiology ; Fatigue - diagnosis ; Headache - epidemiology ; Humans ; ICU ; Long-COVID ; Long-Haulers ; Neuro-COVID-19 ; PCNS ; Post-Acute COVID-19 Syndrome ; Post-COVID-19 neurological syndrome ; Post-COVID-19 syndrome ; Review ; SARS-CoV-2</subject><ispartof>Journal of the neurological sciences, 2022-03, Vol.434, p.120162-120162, Article 120162</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><rights>2022 Elsevier B.V. All rights reserved. 2022 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c565t-1612d75d530a884baa48e0680d6c2b354096be69d76c07dac97f9bf19683c2273</citedby><cites>FETCH-LOGICAL-c565t-1612d75d530a884baa48e0680d6c2b354096be69d76c07dac97f9bf19683c2273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022510X22000211$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35121209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Premraj, Lavienraj</creatorcontrib><creatorcontrib>Kannapadi, Nivedha V.</creatorcontrib><creatorcontrib>Briggs, Jack</creatorcontrib><creatorcontrib>Seal, Stella M.</creatorcontrib><creatorcontrib>Battaglini, Denise</creatorcontrib><creatorcontrib>Fanning, Jonathon</creatorcontrib><creatorcontrib>Suen, Jacky</creatorcontrib><creatorcontrib>Robba, Chiara</creatorcontrib><creatorcontrib>Fraser, John</creatorcontrib><creatorcontrib>Cho, Sung-Min</creatorcontrib><title>Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis</title><title>Journal of the neurological sciences</title><addtitle>J Neurol Sci</addtitle><description>Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis.
To determine the prevalence of neurological and neuropsychiatric symptoms reported 12 weeks (3 months) or more after acute COVID-19 onset in adults.
A systematic search of PubMed, EMBASE, Web of Science, Google Scholar and Scopus was conducted for studies published between January 1st, 2020 and August 1st, 2021. The systematic review was guided by Preferred Reporting Items for Systematic Review and Meta-Analyses.
Studies were included if the length of follow-up satisfied the National Institute for Healthcare Excellence (NICE) definition of post-COVID-19 syndrome (symptoms that develop or persist ≥3 months after the onset of COVID-19). Additional criteria included the reporting of neurological or neuropsychiatric symptoms in individuals with COVID-19.
Two authors independently extracted data on patient characteristics, hospital and/or ICU admission, acute-phase COVID-19 symptoms, length of follow-up, and neurological and neuropsychiatric symptoms.
The primary outcome was the prevalence of neurological and neuropsychiatric symptoms reported ≥3 months post onset of COVID-19. We also compared post-COVID-19 syndrome in hospitalised vs. non-hospitalised patients, with vs. without ICU admission during the acute phase of infection, and with mid-term (3 to 6 months) and long-term (>6 months) follow-up.
Of 1458 articles, 18 studies, encompassing a total of 10,530 patients, were analysed. Overall prevalence for neurological post-COVID-19 symptoms were: fatigue (37%, 95% CI: 25%–48%), brain fog (32%, 10%–54%), memory issues (28%, 22%–35%), attention disorder (22%, 7%–36%), myalgia (17%, 9%–25%), anosmia (12%, 8%–16%), dysgeusia (10%, 6%–14%) and headache (15%, 4%–26%). Neuropsychiatric conditions included sleep disturbances (31%, 19%–42%), anxiety (23%, 14%–32%) and depression (17%, 10%–24%). Neuropsychiatric symptoms substantially increased in prevalence between mid- and long-term follow-up. Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety, depression, dysgeusia, fatigue, headache, myalgia, and sleep disturbance at three (or more) months post-infection. Cohorts with >20% of patients admitted to the ICU during acute COVID-19 experienced higher prevalence of fatigue, anxiety, depression, and sleep disturbances than cohorts with <20% of ICU admission.
Fatigue, cognitive dysfunction (brain fog, memory issues, attention disorder) and sleep disturbances appear to be key features of post-COVID-19 syndrome. Psychiatric manifestations (sleep disturbances, anxiety, and depression) are common and increase significantly in prevalence over time. Randomised controlled trials are necessary to develop intervention strategy to reduce disease burden.
•Question: How commonly are neurological and neuropsychiatric symptoms reported three months or more after acute COVID-19 onset in adults?•Findings: In a meta-analysis of 18 studies encompassing 10,530 patients (hospitalised and non-hospitalised), overall prevalence for neurological symptoms three months after COVID-19 onset was: fatigue (37%), brain fog (32%), memory issues (28%), attention disorder (22%), myalgia (17%), anosmia (12%), dysgeusia (10%), and headache (15%). The prevalence of neuropsychiatric symptoms was sleep disturbances (31%), anxiety (23%), and depression (17%).•Meaning: Given the high prevalence of neurological and neuropsychiatric post-COVID-19 syndrome, randomised controlled trials are necessary to develop intervention strategy to reduce disease burden.</description><subject>Adult</subject><subject>Anxiety - epidemiology</subject><subject>Anxiety - etiology</subject><subject>Anxiety - psychology</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>Fatigue - diagnosis</subject><subject>Headache - epidemiology</subject><subject>Humans</subject><subject>ICU</subject><subject>Long-COVID</subject><subject>Long-Haulers</subject><subject>Neuro-COVID-19</subject><subject>PCNS</subject><subject>Post-Acute COVID-19 Syndrome</subject><subject>Post-COVID-19 neurological syndrome</subject><subject>Post-COVID-19 syndrome</subject><subject>Review</subject><subject>SARS-CoV-2</subject><issn>0022-510X</issn><issn>1878-5883</issn><issn>1878-5883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1vFCEYx4nR2LX6AbwYjl5YgVkY0MSkWd-a1PSixhth4JktmxlYgW2y3162Wxu9eCJ5_i888EPoJaNLRpl8s11uY1lyyvmS8Tbgj9CCqV4RoVT3GC1oU4hg9OcZelbKllIqldJP0VknGG8JvUDz1-CxjR5PKW5IhTzjCPucprQJzk530t1gVw7uJtiag8OzjWGEUm0NKRacRrxLpZL19Y_LD4RpXA7R5zTDW3yBZ6iW2GinQwnlOXoy2qnAi_vzHH3_9PHb-gu5uv58ub64Ik5IUQmTjPteeNFRq9RqsHaloO1OvXR86MSKajmA1L6XjvbeOt2PehiZlqpznPfdOXp_6t3thxm8g1izncwuh9nmg0k2mH-VGG7MJt0a1Wule9EKXt8X5PRr355q5lAcTJONkPbFcMklZWKlj1Z2srqcSskwPlzDqDliMlvTMJkjJnPC1DKv_t7vIfGHSzO8Oxmg_dJtgGyKCxAd-JDBVeNT-E_9bxrIpHE</recordid><startdate>20220315</startdate><enddate>20220315</enddate><creator>Premraj, Lavienraj</creator><creator>Kannapadi, Nivedha V.</creator><creator>Briggs, Jack</creator><creator>Seal, Stella M.</creator><creator>Battaglini, Denise</creator><creator>Fanning, Jonathon</creator><creator>Suen, Jacky</creator><creator>Robba, Chiara</creator><creator>Fraser, John</creator><creator>Cho, Sung-Min</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220315</creationdate><title>Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis</title><author>Premraj, Lavienraj ; Kannapadi, Nivedha V. ; Briggs, Jack ; Seal, Stella M. ; Battaglini, Denise ; Fanning, Jonathon ; Suen, Jacky ; Robba, Chiara ; Fraser, John ; Cho, Sung-Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c565t-1612d75d530a884baa48e0680d6c2b354096be69d76c07dac97f9bf19683c2273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Anxiety - epidemiology</topic><topic>Anxiety - etiology</topic><topic>Anxiety - psychology</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>Fatigue - diagnosis</topic><topic>Headache - epidemiology</topic><topic>Humans</topic><topic>ICU</topic><topic>Long-COVID</topic><topic>Long-Haulers</topic><topic>Neuro-COVID-19</topic><topic>PCNS</topic><topic>Post-Acute COVID-19 Syndrome</topic><topic>Post-COVID-19 neurological syndrome</topic><topic>Post-COVID-19 syndrome</topic><topic>Review</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Premraj, Lavienraj</creatorcontrib><creatorcontrib>Kannapadi, Nivedha V.</creatorcontrib><creatorcontrib>Briggs, Jack</creatorcontrib><creatorcontrib>Seal, Stella M.</creatorcontrib><creatorcontrib>Battaglini, Denise</creatorcontrib><creatorcontrib>Fanning, Jonathon</creatorcontrib><creatorcontrib>Suen, Jacky</creatorcontrib><creatorcontrib>Robba, Chiara</creatorcontrib><creatorcontrib>Fraser, John</creatorcontrib><creatorcontrib>Cho, Sung-Min</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Premraj, Lavienraj</au><au>Kannapadi, Nivedha V.</au><au>Briggs, Jack</au><au>Seal, Stella M.</au><au>Battaglini, Denise</au><au>Fanning, Jonathon</au><au>Suen, Jacky</au><au>Robba, Chiara</au><au>Fraser, John</au><au>Cho, Sung-Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis</atitle><jtitle>Journal of the neurological sciences</jtitle><addtitle>J Neurol Sci</addtitle><date>2022-03-15</date><risdate>2022</risdate><volume>434</volume><spage>120162</spage><epage>120162</epage><pages>120162-120162</pages><artnum>120162</artnum><issn>0022-510X</issn><issn>1878-5883</issn><eissn>1878-5883</eissn><abstract>Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis.
To determine the prevalence of neurological and neuropsychiatric symptoms reported 12 weeks (3 months) or more after acute COVID-19 onset in adults.
A systematic search of PubMed, EMBASE, Web of Science, Google Scholar and Scopus was conducted for studies published between January 1st, 2020 and August 1st, 2021. The systematic review was guided by Preferred Reporting Items for Systematic Review and Meta-Analyses.
Studies were included if the length of follow-up satisfied the National Institute for Healthcare Excellence (NICE) definition of post-COVID-19 syndrome (symptoms that develop or persist ≥3 months after the onset of COVID-19). Additional criteria included the reporting of neurological or neuropsychiatric symptoms in individuals with COVID-19.
Two authors independently extracted data on patient characteristics, hospital and/or ICU admission, acute-phase COVID-19 symptoms, length of follow-up, and neurological and neuropsychiatric symptoms.
The primary outcome was the prevalence of neurological and neuropsychiatric symptoms reported ≥3 months post onset of COVID-19. We also compared post-COVID-19 syndrome in hospitalised vs. non-hospitalised patients, with vs. without ICU admission during the acute phase of infection, and with mid-term (3 to 6 months) and long-term (>6 months) follow-up.
Of 1458 articles, 18 studies, encompassing a total of 10,530 patients, were analysed. Overall prevalence for neurological post-COVID-19 symptoms were: fatigue (37%, 95% CI: 25%–48%), brain fog (32%, 10%–54%), memory issues (28%, 22%–35%), attention disorder (22%, 7%–36%), myalgia (17%, 9%–25%), anosmia (12%, 8%–16%), dysgeusia (10%, 6%–14%) and headache (15%, 4%–26%). Neuropsychiatric conditions included sleep disturbances (31%, 19%–42%), anxiety (23%, 14%–32%) and depression (17%, 10%–24%). Neuropsychiatric symptoms substantially increased in prevalence between mid- and long-term follow-up. Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety, depression, dysgeusia, fatigue, headache, myalgia, and sleep disturbance at three (or more) months post-infection. Cohorts with >20% of patients admitted to the ICU during acute COVID-19 experienced higher prevalence of fatigue, anxiety, depression, and sleep disturbances than cohorts with <20% of ICU admission.
Fatigue, cognitive dysfunction (brain fog, memory issues, attention disorder) and sleep disturbances appear to be key features of post-COVID-19 syndrome. Psychiatric manifestations (sleep disturbances, anxiety, and depression) are common and increase significantly in prevalence over time. Randomised controlled trials are necessary to develop intervention strategy to reduce disease burden.
•Question: How commonly are neurological and neuropsychiatric symptoms reported three months or more after acute COVID-19 onset in adults?•Findings: In a meta-analysis of 18 studies encompassing 10,530 patients (hospitalised and non-hospitalised), overall prevalence for neurological symptoms three months after COVID-19 onset was: fatigue (37%), brain fog (32%), memory issues (28%), attention disorder (22%), myalgia (17%), anosmia (12%), dysgeusia (10%), and headache (15%). The prevalence of neuropsychiatric symptoms was sleep disturbances (31%), anxiety (23%), and depression (17%).•Meaning: Given the high prevalence of neurological and neuropsychiatric post-COVID-19 syndrome, randomised controlled trials are necessary to develop intervention strategy to reduce disease burden.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35121209</pmid><doi>10.1016/j.jns.2022.120162</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-510X |
| ispartof | Journal of the neurological sciences, 2022-03, Vol.434, p.120162-120162, Article 120162 |
| issn | 0022-510X 1878-5883 1878-5883 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8798975 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Anxiety - epidemiology Anxiety - etiology Anxiety - psychology COVID-19 COVID-19 - complications COVID-19 - epidemiology Fatigue - diagnosis Headache - epidemiology Humans ICU Long-COVID Long-Haulers Neuro-COVID-19 PCNS Post-Acute COVID-19 Syndrome Post-COVID-19 neurological syndrome Post-COVID-19 syndrome Review SARS-CoV-2 |
| title | Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T01%3A37%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mid%20and%20long-term%20neurological%20and%20neuropsychiatric%20manifestations%20of%20post-COVID-19%20syndrome:%20A%20meta-analysis&rft.jtitle=Journal%20of%20the%20neurological%20sciences&rft.au=Premraj,%20Lavienraj&rft.date=2022-03-15&rft.volume=434&rft.spage=120162&rft.epage=120162&rft.pages=120162-120162&rft.artnum=120162&rft.issn=0022-510X&rft.eissn=1878-5883&rft_id=info:doi/10.1016/j.jns.2022.120162&rft_dat=%3Cproquest_pubme%3E2626015495%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2626015495&rft_id=info:pmid/35121209&rft_els_id=S0022510X22000211&rfr_iscdi=true |